High-grade gliomas in adolescents and young adults highlight histomolecular differences from their adult and pediatric counterparts.
DNA-methylation analysis
glioblastoma
glioma
integrated diagnosis
whole exome sequencing
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
17 08 2020
17 08 2020
Historique:
pubmed:
7
2
2020
medline:
7
4
2021
entrez:
7
2
2020
Statut:
ppublish
Résumé
Considering that pediatric high-grade gliomas (HGGs) are biologically distinct from their adult counterparts, the objective of this study was to define the landscape of HGGs in adolescents and young adults (AYAs). We performed a multicentric retrospective study of 112 AYAs from adult and pediatric Ile-de-France neurosurgical units, treated between 1998 and 2013 to analyze their clinicoradiological and histomolecular profiles. The inclusion criteria were age between 15 and 25 years, histopathological HGG diagnosis, available clinical data, and preoperative and follow-up MRI. MRI and tumoral samples were centrally reviewed. Immunohistochemistry and complementary molecular techniques such as targeted/next-generation sequencing, whole exome sequencing, and DNA-methylation analyses were performed to achieve an integrated diagnosis according to the 2016 World Health Organization (WHO) classification. Based on 80 documented AYA patients, HGGs constitute heterogeneous clinicopathological and molecular groups, with a predominant representation of pediatric subtypes (histone H3-mutants, 40%) but also adult subtypes (isocitrate dehydrogenase [IDH] mutants, 28%) characterized by the rarity of oligodendrogliomas, IDH mutants, and 1p/19q codeletion and the relative high frequency of "rare adult IDH mutations" (20%). H3G34-mutants (14%) represent the most specific subgroup in AYAs. In the H3K27-mutant subgroup, non-brainstem diffuse midline gliomas are more frequent (66.7%) than diffuse intrinsic pontine gliomas (23.8%), contrary to what is observed in children. We found that WHO grade has no prognostic value, but molecular subgrouping has major prognostic importance. HGGs in AYAs could benefit from a specific classification, driven by molecular subtyping rather than age group. Collaborative efforts are needed from pediatric and adult neuro-oncology teams to improve the management of HGGs in AYAs.
Sections du résumé
BACKGROUND
Considering that pediatric high-grade gliomas (HGGs) are biologically distinct from their adult counterparts, the objective of this study was to define the landscape of HGGs in adolescents and young adults (AYAs).
METHODS
We performed a multicentric retrospective study of 112 AYAs from adult and pediatric Ile-de-France neurosurgical units, treated between 1998 and 2013 to analyze their clinicoradiological and histomolecular profiles. The inclusion criteria were age between 15 and 25 years, histopathological HGG diagnosis, available clinical data, and preoperative and follow-up MRI. MRI and tumoral samples were centrally reviewed. Immunohistochemistry and complementary molecular techniques such as targeted/next-generation sequencing, whole exome sequencing, and DNA-methylation analyses were performed to achieve an integrated diagnosis according to the 2016 World Health Organization (WHO) classification.
RESULTS
Based on 80 documented AYA patients, HGGs constitute heterogeneous clinicopathological and molecular groups, with a predominant representation of pediatric subtypes (histone H3-mutants, 40%) but also adult subtypes (isocitrate dehydrogenase [IDH] mutants, 28%) characterized by the rarity of oligodendrogliomas, IDH mutants, and 1p/19q codeletion and the relative high frequency of "rare adult IDH mutations" (20%). H3G34-mutants (14%) represent the most specific subgroup in AYAs. In the H3K27-mutant subgroup, non-brainstem diffuse midline gliomas are more frequent (66.7%) than diffuse intrinsic pontine gliomas (23.8%), contrary to what is observed in children. We found that WHO grade has no prognostic value, but molecular subgrouping has major prognostic importance.
CONCLUSIONS
HGGs in AYAs could benefit from a specific classification, driven by molecular subtyping rather than age group. Collaborative efforts are needed from pediatric and adult neuro-oncology teams to improve the management of HGGs in AYAs.
Identifiants
pubmed: 32025728
pii: 5728472
doi: 10.1093/neuonc/noaa024
pmc: PMC7594566
doi:
Substances chimiques
Isocitrate Dehydrogenase
EC 1.1.1.41
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1190-1202Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Acta Neuropathol. 2016 Oct;132(4):625-34
pubmed: 27573687
Nat Genet. 2014 May;46(5):444-450
pubmed: 24705251
Neurosurgery. 2020 Apr 1;86(4):517-523
pubmed: 31342064
Neuro Oncol. 2011 Oct;13(10):1049-58
pubmed: 21784756
Cancer Cell. 2012 Oct 16;22(4):425-37
pubmed: 23079654
J Clin Oncol. 2010 Jun 20;28(18):3061-8
pubmed: 20479398
PLoS One. 2012;7(2):e30313
pubmed: 22389665
Acta Neuropathol. 2015 Dec;130(6):815-27
pubmed: 26399631
Neuro Oncol. 2013 Jan;15(1):112-21
pubmed: 23223340
Acta Neuropathol. 2013 May;125(5):659-69
pubmed: 23417712
Neuro Oncol. 2017 Aug 1;19(8):1025-1034
pubmed: 28371920
Brain Pathol. 2016 Mar;26(2):206-14
pubmed: 26206478
J Neuroradiol. 2018 Sep;45(5):316-322
pubmed: 29505840
Eur J Neurol. 2015 Feb;22(2):348-54
pubmed: 25318355
Nat Rev Cancer. 2014 Feb;14(2):92-107
pubmed: 24457416
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Cancer Cell. 2017 Oct 9;32(4):520-537.e5
pubmed: 28966033
Acta Neuropathol. 2015 Sep;130(3):435-7
pubmed: 26231952
Acta Neuropathol Commun. 2014 Feb 18;2:23
pubmed: 24548782
Acta Neuropathol Commun. 2017 Oct 30;5(1):78
pubmed: 29084603
Adolesc Health Med Ther. 2017 Sep 22;8:99-113
pubmed: 28989289
J Clin Oncol. 2011 Oct 20;29(30):3999-4006
pubmed: 21931021
J Clin Oncol. 2018 Apr 1;36(10):951-958
pubmed: 29412784
Acta Neuropathol. 2017 Dec;134(6):965-967
pubmed: 29027579
Nat Med. 2016 Nov;22(11):1314-1320
pubmed: 27748748
Acta Neuropathol. 2017 Jun;133(6):1001-1016
pubmed: 28255664
Acta Neuropathol. 2016 Feb;131(2):309-319
pubmed: 26493382
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
Acta Neuropathol Commun. 2016 Aug 08;4(1):79
pubmed: 27503138
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Neuro Oncol. 2010 Feb;12(2):153-63
pubmed: 20150382
Acta Neuropathol. 2015 May;129(5):669-78
pubmed: 25752754
Nat Genet. 2014 May;46(5):462-6
pubmed: 24705250
J Neurosurg Pediatr. 2018 Mar;21(3):247-257
pubmed: 29271729
Cancer Cell. 2013 Nov 11;24(5):660-72
pubmed: 24183680
Pediatr Blood Cancer. 2018 Jan;65(1):
pubmed: 28792659
Neuro Oncol. 2017 May 1;19(5):699-709
pubmed: 28453743
Neuro Oncol. 2011 Feb;13(2):212-22
pubmed: 21138945
Radiology. 2019 Dec;293(3):633-643
pubmed: 31592732
Neuro Oncol. 2020 Jan 11;22(1):116-127
pubmed: 31419298
Nature. 2012 Jan 29;482(7384):226-31
pubmed: 22286061
Childs Nerv Syst. 2011 Jan;27(1):87-94
pubmed: 20725730
PLoS One. 2016 Jun 02;11(6):e0156422
pubmed: 27253461
Oncotarget. 2016 Jan 26;7(4):5030-41
pubmed: 26452024
AJNR Am J Neuroradiol. 2017 Apr;38(4):795-800
pubmed: 28183840
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931